What is it used for?
All products
Digestive enzyme(s).
Digestive aid.
Products containing proteases (Table 2)
Helps digest proteins [Source note 1].
Products containing pancreatic enzymes
Digestive aid to help decrease bloating after high caloric, high fat meals [Source note 2].
Helps to decrease bloating after high caloric, high fat meals [Source note 3].
Products containing alpha-galactosidase
Helps prevent gastrointestinal intolerance of oligosaccharides/fermentable carbohydrates [Source note 4].
Helps reduce gas production/flatulence following a meal rich in oligosaccharides/fermentable carbohydrates (such as vegetables, pulses/legumes/beans and whole grains) [Source note 5].
Products containing bromelain
Used in Herbal Medicine to help relieve minor pain, swelling and inflammation [Source note 6].
Products containing lactase
Assist in the digestion of foods containing lactose (e.g., dairy foods, milk, etc.) [Source note 7].
Helps prevent symptoms of lactose intolerance (including gas, bloating, cramping, and diarrhea) [Source note 8].
What this guide covers
Any ingredient in Tables 1 to 3 may be formulated as single ingredient products, or two or more ingredients may be combined to form multi-ingredient products.
The enzyme nomenclature identification number (IUBMB No.) is not required but may be provided as additional information on the cover letter.
The
Rules when this reference is combined with other references (source review category II and III):
Liquid and liquid-containing dosage forms (e.g., capsule, soft; spray) are not acceptable as source review category II when an enzyme is combined with non-enzymatic ingredients as this may impact the enzyme activity. These products may be submitted as a source review category III.
However, this restriction does not apply if the enzymes are microencapsulated (i.e., Capsule, enteric-coated pellets and Tablet, enteric-coated granules).
Who does this guide cover?
Adults 18 years and older
How is it taken?
Oral
Which forms are covered?
this reference excludes foods or food-like dosage forms as indicated in the Compendium of references Guidance Document.
It includes the dosage forms listed below for pancreatic enzymes.
Pancreatic enzymes; pancreatic extract; pancreatin; pancrelipase:
The only acceptable dosage forms are: Capsule, enteric-coated; Capsule, soft, enteric-coated; Capsule, enteric-coated pellets; Granule enteric-coated; Tablet, enteric-coated; Tablets, enteric-coated granules.
Quantities
| active ingredients | Quantities (enzymatic activity per day; and per single dose, when applicable)¹,² |
|---|---|
| alpha-Amylase | No to exceed 150,000 FCC DU per day; and 34,000 FCC DU per single dose |
| alpha-Galactosidase | Digestive enzyme/Digestive aid Not to exceed 3,000 FCC GalU per day |
| alpha-Galactosidase | Prevention of gastrointestinal intolerance/Reduction of flatulence 260 - 3,000 FCC GalU per day |
| Bacterial protease | Not to exceed 490,000 FCC PC per day |
| beta-Glucanase | Not to exceed 210 FCC BGU per day |
| Bromelain | Digestive enzyme/Digestive aid/Digest proteins Not to exceed 130,000,000 FCC PU per day; and 45,000,000 FCC PU per single dose |
| Bromelain | Minor pain, swelling, and inflammation relief 480,000 - 130,000,000 FCC PU per day; Not to exceed 45,000,000 FCC PU per single dose |
| Catalase | Not to exceed 3,200 FCC BU per day |
| Cellulase | Not to exceed 110,000 FCC CU per day |
| Chymotrypsin | Not to exceed 480,000 USP CchyUmotrypsin units per day; and 160,000 USP CchyUmotrypsin units per single dose |
| Diastase | Not to exceed 6,000 FCC DP per day |
| Fungal protease | Not to exceed 680,000 FCC HUT and/or 6,800 FCC SAP per day |
| Glucoamylase (Amyloglucosidase) | Not to exceed 300 FCC GU per day |
| Hemicellulase | Not to exceed 45,000 FCC HCU per day |
| Invertase/sucrase | Not to exceed 3,000 FCC INVU and/or 4,200 FCC SU per day |
| Lactase | Digestive enzyme/Digestive aid Not to exceed 54,000 FCC ALU per day; and 18,000 FCC ALU per single dose |
| Lactase | Lactose digestion/Symptoms of lactose intolerance 3,000 - 54,000 FCC ALU per day; and not to exceed 18,000 FCC ALU per single dose |
| Lipase | Not to exceed 110,000 FCC LU per day; and 30,000 FCC LU per single dose |
| Malt diastase | Not to exceed 6,000 FCC DP per day |
| Pancreatic enzymes; pancreatic extract; pancreatin; pancrelipase³ |
|
| Papain | Not to exceed 7,200,000 FCC PU per day; and 2,400,000 FCC PU per single dose |
| Pectinase | Not to exceed 180 endo-PG per day |
| Pepsin | Not to exceed 1,900,000 FCC PepU per day |
| Phytase | Not to exceed 75 FCC FTU per day |
| Trypsin | Not to exceed 1,200,000 USP TrypU per day; and 400,000 USP TrypU per single dose |
| Xylanase | Not to exceed 3,300 XU |
References: alpha-Amylase: FCC 2024; Glade et al. 2001; alpha-Galactosidase: FCC 2024; Di Stefano et al. 1999; Domínguez-Muñoz et al. 1997; Other enzymes: source authority 2012.
¹When multiple enzymes are combined, the total activity of each enzyme in the finished product must not exceed the maximum single and daily activities listed in Table 4. ²Other recognized enzymatic activity units may be listed on the product label as long as equivalent to the ones indicated on this reference and product documentation form. ³Pharmacopoeial units other than USP may be represented on the label as additional information. The following approximate conversion factors can be used to convert the activities of pancreatic enzymes (including pancreatic extract, pancreatin, pancrelipase) into USP units [Source note 10]:
Amylase: 1 Ph. Eur. unit = 1 BP unit = 1 FIP unit ~ 4.15 USP units
Lipase: 1 Ph. Eur. unit = 1 BP unit = 1 FIP unit ~ 1 USP unit
Protease: 1 Ph. Eur. unit = 1 BP unit = 1 FIP unit ~ 62.5 USP units
Note: The quantity per dosage unit must be the enzymatic activity. The quantity of the enzymatic preparation in mg or ml may also be included as additional quantity.
How is it used?
All products; Optional for bromelain used for minor pain, swelling, and inflammation relief
Take with (or immediately before) a meal/food.¹
¹Note: This directions for use statement can be adjusted on the product label to provide clear instructions to consumers. If the product contains multiple digestive enzymes and associated claims, the directions should be linked to each claim and may be modified to include additional details (e.g., "For lactose intolerance, take with each meal containing lactose"). Additional information, such as “Do not exceed (X capsules per single dose and) Y capsules per day” may replace the dosing information when there is no established minimum dose associated with a claim.
Products containing pancreatic enzymes; pancreatic extract; pancreatin; pancrelipase
Use the smallest effective dose which controls symptoms [Source note 11].
Capsule, enteric-coated; Capsule, soft, enteric-coated; Capsule, enteric-coated pellets; Granule enteric-coated; Tablet, enteric-coated; Tablets, enteric-coated granules
Swallow whole. Do not crush or chew [Source note 12].
Capsule, enteric-coated pellets; Tablets, enteric-coated granules
(For individuals who experience difficulties swallowing) Capsules/Tablets may be opened and the content may be mixed with soft food or fluid. Use immediately after mixing [Source note 13].
How long is it used?
Products providing 60,000,000 FCC PU or less bromelain, per day
Ask a healthcare professional for use beyond 16 weeks [Source note 14].
Products providing more than 60,000,000 FCC PU bromelain, per day and products containing pancreatic enzymes; pancreatic extract; pancreatin; pancrelipase
Ask a healthcare professional for use beyond 4 weeks.
Products containing any other enzyme from Tables 1, 2 and 3
Ask a healthcare professional for use beyond 4 to 8 weeks¹.
¹Note: The term ‘prolonged use ’used in previous version of the reference has been further defined to avoid confusion.
Warnings and precautions
All products
Ask a healthcare professional before use if you are pregnant or breastfeeding.
Products containing one or more carbohydrases (Table 1); cellulase; lactase; pancreatic enzymes; pancreatic extract; pancreatin; pancrelipase
Ask a healthcare professional before use if you have diabetes.
Products containing one or more proteases (Table 2); chymotrypsin; bromelain; papain; trypsin
Ask a healthcare professional before use if you have gastrointestinal lesions/ulcers or are having surgery.
Ask a healthcare professional before use if you are taking blood thinners or anti-inflammatory medications.
Products containing papain
Ask a healthcare professional before use if you have an allergy to latex or fruits (such as avocado, banana, chestnut, passion fruit, fig, melon, mango, kiwi, pineapple, peach, and tomato) [Source note 15].
Products containing pancreatic enzymes; pancreatic extract; pancreatin; pancrelipase
Ask a healthcare professional before use if you have pancreatitis, pancreatic exocrine insufficiency or cystic fibrosis [Source note 16].
Prevention of gastrointestinal intolerance/Reduction of flatulence/Minor pain, swelling, and inflammation relief/Lactose digestion/Symptoms of lactose intolerance/Digestive aid/Decrease bloating
Ask a healthcare professional if symptoms persist or worsen.
When should it be avoided?
Products containing pancreatic enzymes; pancreatic extract; pancreatin; pancrelipase
Do not use if you are sensitive to pancreatic enzymes [Source note 17].
Products sourced from Sus scrofa pancreas
Do not use if you are sensitive to pork proteins [Source note 18].
Possible side effects
All products
Stop use if hypersensitivity/allergy occurs [Source note 19].
Products containing lactase
Stop use if gastrointestinal discomfort/disturbances occur [Source note 20].
Products containing pancreatic enzymes; pancreatic extract; pancreatin; pancrelipase
Stop use and ask a healthcare professional if nausea, vomiting, abdominal pain/epigastric pain, and/or heartburn occur [Source note 21].
Products containing bromelain
When using this product you may experience gastrointestinal discomfort/disturbances [Source note 22].
Storage
Must be established in accordance with the requirements described in the applicable product regulations.
Conditions for combined preparations
For multi-ingredient products containing bromelain and papain, the maximum enzymatic activity from both enzymes combined cannot exceed the maximum proteolytic activity of 130,000,000 FCC PU per day and 45,000,000 FCC PU per single dose.
For multi-ingredient products containing diastase and malt diastase, the maximum enzymatic activity from both enzymes combined cannot exceed 6,000 FCC DP per day.
Appendix I
Definitions of the activity units listed in 4:
ALU: One lactase unit (ALU) is defined as the quantity of enzyme that will liberate o-nitrophenol at a rate of 1 μmol/minute under the conditions of the assay.
BGU: One β-glucanase unit (BGU) is defined as the quantity of enzyme that will liberate reducing sugar (as glucose equivalence) at a rate of 1 μmol/minute under the conditions of the assay.
BU: One Baker unit is defined as the amount of catalase that will decompose 264 mg of hydrogen peroxide under the conditions of the assay.
ChyU: One USP chymotrypsin unit (ChyU) is defined as the activity causing a change in absorbance at the rate of 0.0075/minute under the conditions of the assay.
CU: One cellulase unit (CU) is defined as the amount of activity that will produce a relative fluidity change of 1 in 5 minutes in a defined carboxymethyl cellulose substrate under the conditions of the assay.
DP (or DDPU): One unit of diastase activity, expressed as degrees diastatic power (DP°), is defined as the amount of enzyme contained in 0.1 mL of a 5% solution of the sample enzyme preparation that will produce sufficient reducing sugars to reduce 5 mL of Fehling's solution when the sample is incubated with 100 mL of the substrate for 1 hour at 20°C.
DU: One α-amylase dextrinizing unit (DU) is defined as the quantity of α-amylase that will dextrinize soluble starch in the presence of an excess of β-amylase at the rate of 1 g/hour at 30°C.
endo-PG: One endo-polygalacturonase unit (endo-PG) is the amount of enzyme required to release 1 µmol/minute of galacturonic acid from polygalacturonic acid under the conditions of the assay.
FTU: One phytase unit (FTU) is the amount of enzyme that liberates inorganic phosphate at 1 μmol/minute from 0.0051 mol/L of sodium phytate at 37ºC and pH 5.50 under the conditions of the test.
GaIU: One galactosidase activity unit (GalU) is defined as the quantity of the enzyme that will liberate p-nitrophenol at the rate of 1 μmol/minute under the conditions of the assay.
GU: One glucoamylase unit (GU) is defined as the amount of glucoamylase that will liberate 0.1 μmol/minute of p-nitrophenol from the p-nitrophenyl-α-d-glucopyranoside solution under the conditions of the assay.
HCU: One hemicellulase unit (HCU) is defined as the activity that will produce a relative fluidity change of 1 over a period of 5 minutes in a locust bean gum substrate under the conditions specified.
HUT: One hemoglobin units on the tyrosine basis (HUT) is defined as the amount of enzyme that produces, in 1 minute under the specified conditions, a hydrolysate whose absorbance at 275 nm is the same as that of a solution containing 1.10 μg/mL of tyrosine in 0.006 N hydrochloric acid.
SAP: One spectrophotometric acid protease unit (SAP) is that activity that will liberate 1 μmol of tyrosine per minute under the conditions specified.
INVU: One invertase unit (INVU) is defined as the amount of enzyme that hydrolyzes 1.0 microµmol of sucrose to invert sugar per minute at 55ºC and pH 4.5.
LU: One lipase unit (LU) is defined as the quantity of enzyme that will liberate 1 μmol of butyric acid per minute under the conditions of the test.
PC: One bacterial protease unit (PC) is defined as the quantity of enzyme that produces the equivalent of 1.5 μg/mL of l-tyrosine per minute under the conditions of the assay.
PepU: One pepsin unit (PepU) is defined as the quantity of enzyme that produces the equivalent of 1 µmol of tyrosine per minute under the conditions of the assay.
PU: One papain unit (PU) is defined as the quantity of enzyme that liberates the equivalent of 1 μg of tyrosine per hour under the conditions of the assay. One gelatin digestion unit (GDU) is approximately equivalent to 15,000 FCC papain units (1 GDU ≈ 15,000 FCC PU).
SU: One Sumner unit (SU) is the quantity of enzyme which, under the conditions of the assay, will convert 1 mg of sucrose to glucose and fructose in 5 minutes.
TrypU: One USP trypsin unit (TrypU) is the activity causing a change in the absorbance of 0.003 per minute under the conditions of the assay.
XU: One xylanase unit (XU) is defined as the amount of enzyme that releases 1 µmol of reducing sugar, equivalent to xylose, per minute under specific conditions. These standard conditions include a pH of 5.3 and a temperature of 50°C.
Appendix II
Amylase, lipase and protease activity units per milligram of pancreas preparation according to the British, European and United States pharmacopoeias
| Pharmacopoeia | Enzyme | Units of activity¹ / Amylase | Units of activity¹ / Lipase | Units of activity¹ / Protease |
|---|---|---|---|---|
| BP 2025 | Pancreatin | 24 FIP | 20 FIP | 1.4 FIP |
| USP 2024 | Pancreatin | 25 USP | 2 USP | 25 USP |
| BP 2025 | Pancreatic extract² | 12 Ph. Eur. | 15 Ph. Eur. | 1 Ph. Eur. |
| Ph.Eur. 2025 | Pancreatic extract (powder)² | 12 Ph. Eur. | 15 Ph. Eur. | 1 Ph. Eur. |
| USP 2024 | Pancrelipase | 100 USP | 24 USP | 100 USP |
¹Minimum amounts. ²Cross-referenced within the respective pharmacopoeias. The proper and common name ‘Pancreatic extract’ should be used for both BP 2025 and Ph.Eur 2025.
Preparation details
Ingredient identity, preparation requirements, and other details that define the scope of this guide.
Ingredients and preparations
| Proper name(s) | Common name(s) | Source information / Source material(s) | Source information / Part(s) |
|---|---|---|---|
| 4-alpha-D-Glucan glucanohydrolase | alpha-Amylase |
| Whole |
| 4-alpha-D-Glucan glucanohydrolase | alpha-Amylase | Hordeum vulgare | Seed |
| 4-alpha-D-Glucan glucanohydrolase | alpha-Amylase | Rhizopus oryzae | Whole |
| alpha-D-Galactoside galactohydrolase | alpha-Galactosidase | Aspergillus niger | Whole |
| 1,3-(1,3;1,4)-beta-D-Glucan 3(4)-glucanohydrolase | beta-Glucanase |
| Whole |
|
|
| Whole |
| 4-(1,3;1,4)-beta-D-Glucan 4-glucanohydrolase | Cellulase |
| Whole |
| Diastase | Diastase |
| Whole |
| Hemicellulase |
| Whole |
|
|
| Whole |
| Malt diastase | Malt diastase | Hordeum vulgare | Seed |
|
|
| Whole |
|
|
| Whole |
| Proper name(s) | Common name(s) | Source information / Source material(s) | Source information / Part(s) |
|---|---|---|---|
| Bromelain | Bromelain |
|
|
| Bacterial Protease | Bacterial Protease | Bacillus subtilis | Whole |
| Chymotrypsin | Chymotrypsin |
| Pancreas |
| Fungal protease |
|
| Whole |
| Pancreatic enzymes | Pancreatic enzymes |
| Pancreas |
| Pancreatic extract | Pancreatic extract |
| Pancreas |
| Pancreatin | Pancreatin |
| Pancreas |
| Pancrelipase | Pancrelipase |
| Pancreas |
| Papain | Papain | Carica papaya |
|
| Pepsin | Sus scrofa | Stomach |
| Trypsin | Trypsin |
| Pancreas |
| Proper name(s) | Common name(s) | Source information / Source material(s) | Source information / Part(s) |
|---|---|---|---|
| Hydrogen-peroxide: hydrogen-peroxide oxidoreductase | Catalase |
| Whole |
| beta-D-Galactoside galactohydrolase |
| Aspergillus flavus var. oryzae | Whole |
| Lipase |
| Whole |
|
| Aspergillus niger | Whole |
References Tables 1 to 3: Proper names: BP 2025; IUBMB 2025; Ph.Eu 2025; FCC 2024; USP-NF 2024; WHO 2011; Common names: BP 2025; IUBMB 2025; Ph.Eu 2025; FCC 2024; USP-NF 2024; WHO 2011; Source information: BP 2025; CABI 2025; COL 2025; Ph.Eu 2025; USDA 2025; Brayfield and Cadart 2024; FCC 2024; Kirk 2024; ITIS 2024; RSC 2024; USP-NF 2024; Bisby et al. 2010; Morton 1987.
Other ingredients
Must be chosen from and meet the limitations outlined in the source ingredient database.
Preparation and quality requirements
The finished product specifications must be established in accordance with the requirements described in the source’s product quality guidance.
The active ingredient(s) must comply with the requirements outlined in the source ingredient database.
Details of the manufacturing of the enzyme(s) at the raw material stage should include fermentation medium and the isolation process.
The specifications must include testing for enzymatic activity of the active ingredient(s) at appropriate stages of formulation and manufacturing using the assay outlined in the Food Chemicals Codex (FCC).
Testing for endo-polygalacturonase activity must be done at the appropriate stages of formulation and manufacturing as outlined in Blandino et al. 2002.
Testing for xylanase activity must be done at the appropriate stages of formulation and manufacturing as outlined in Ghose and Bisaria 1987.
Manufacturers are responsible for ensuring that activity assays that are used outside the conditions specified in the FCC have been sufficiently validated for their intended use in accordance with the requirements of good manufacturing practices.
Overages to compensate for the loss of activity during manufacturing and shelf-life of the finished product are permitted as per the pharmacopoeial standard.
Where published assays are not suitable for use, manufacturers should use due diligence to ensure that the enzymes remain active to the end of the shelf-life indicated on the product label.
Pancreatic enzymes: The active ingredient proper name and common name should be determined by the amounts of amylolytic, lipolytic, and proteolytic activities for pancreatin, pancreatic extract, and pancrelipase according to the British, European and United States pharmacopoeias (Appendix II).
Guide change history
Updates to this SupplementSafety.org guide.
Minor updates
Updated guide wording, organization, and source presentation. Added our editorial change history.
Initial release
Initial SupplementSafety.org guide prepared from source reference material.
Validation: Not yet completed. Editorial updates do not constitute clinical validation.
Sources
Source information
This guide organizes source material about uses, preparations, amounts, and precautions. Read the conditions alongside each statement; the information may apply only to particular preparations or populations.
The source document includes supporting references. We have not independently summarized or assessed every cited study for this guide.
- Source document version
- June 26, 2026
- Source captured
- Aug 15, 2026
- Editorial work
- Editorial preparation. Independent clinical review has not been recorded for this guide.
Full citations are available through the link above. Verification is required to open them; reading this guide does not require verification.
Taking a medication too?
Explore our supplement–medication interaction checker. Its coverage and review status are shown with the results; a missing finding does not establish that a combination is safe.
